- Home
- CHRS vs SEER Comparison
CHRS vs SEER Comparison
Compare CHRS & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SEER
- Stock Information
- Founded
- CHRS 2010
- SEER 2017
- Country
- CHRS United States
- SEER United States
- Employees
- CHRS 177
- SEER N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SEER Medicinal Chemicals and Botanical Products
- Sector
- CHRS Health Care
- SEER Health Care
- Exchange
- CHRS Nasdaq
- SEER Nasdaq
- Market Cap
- CHRS 149.9M
- SEER 113.8M
- IPO Year
- CHRS 2014
- SEER 2020
- Fundamental
- Price
- CHRS $1.37
- SEER $2.03
- Analyst Decision
- CHRS Strong Buy
- SEER
- Analyst Count
- CHRS 4
- SEER 0
- Target Price
- CHRS $4.51
- SEER N/A
- AVG Volume (30 Days)
- CHRS 1.4M
- SEER 141.2K
- Earning Date
- CHRS 11-05-2025
- SEER 11-05-2025
- Dividend Yield
- CHRS N/A
- SEER N/A
- EPS Growth
- CHRS N/A
- SEER N/A
- EPS
- CHRS 1.55
- SEER N/A
- Revenue
- CHRS $272,209,000.00
- SEER $16,288,000.00
- Revenue This Year
- CHRS N/A
- SEER $27.77
- Revenue Next Year
- CHRS $126.00
- SEER $20.28
- P/E Ratio
- CHRS $0.88
- SEER N/A
- Revenue Growth
- CHRS 52.33
- SEER 10.52
- 52 Week Low
- CHRS $0.66
- SEER $1.59
- 52 Week High
- CHRS $2.43
- SEER $2.63
- Technical
- Relative Strength Index (RSI)
- CHRS 73.83
- SEER 44.72
- Support Level
- CHRS $1.26
- SEER $1.97
- Resistance Level
- CHRS $1.39
- SEER $2.11
- Average True Range (ATR)
- CHRS 0.08
- SEER 0.06
- MACD
- CHRS 0.02
- SEER -0.00
- Stochastic Oscillator
- CHRS 94.10
- SEER 32.43
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.